CMS To Fund Clinical Trials Evaluating Off-Label Use Of Avastin, Erbitux
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the agency’s proposed national coverage decision for colorectal therapies, CMS will fund costs of experimental drugs and routine care in nine National Cancer Institute trials. Use of Avastin in patients with colorectal cancer in the adjuvant setting and use of Erbitux in head and neck cancers are among the indications being studied in the NCI trials.